Gene expression patterns that characterize advanced stage serous ovarian cancers

被引:90
作者
Lancaster, JM
Dressman, HK
Whitaker, RS
Havrilesky, L
Gray, J
Marks, JR
Nevins, JR
Berchuck, A
机构
[1] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Genet, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA
[4] Univ Wales Coll Cardiff, Inst Med Genet, Cardiff CF1 3NS, S Glam, Wales
关键词
ovarian cancer; microarray analysis; immune function; survival;
D O I
10.1016/j.jsgi.2003.07.004
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To identify gene expression patterns that characterize advanced stage serous ovarian cancers by using microarray expression analysis. METHODS: Using genome-wide expression analysis, we compared a series of 31 advanced stage (III or IV) serous ovarian cancers from patients who survived either less than 2 years or more than 7 years with three normal ovarian epithelial samples. Array findings were validated by analysis of expression of the insulin-like growth factor binding protein 2 (IGFBP2) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) genes using. quantitative real-time polymerase chain reaction (QRT-PCR). RESULTS: Hierarchical clustering identified patterns of gene expression that distinguished cancer from normal ovarian epithelium. We also identified gene expression patterns that distinguish cancers on the basis of patient survival. These genes include many that are associated with immune function. Expression of IGFBP2 and TRAIL genes measured by array and QRT-PCR analysis demonstrated correlation coefficients of 0.63 and 0.78, respectively. CONCLUSION: Global expression analysis can identify expression patterns and individual genes that contribute to ovarian cancer development and outcome. Many of the genes that determine ovarian cancer survival are associated with the immune response, suggesting that immune function influences ovarian cancer virulence. With the generation of newer arrays with more transcripts, larger studies are possible to fully characterize genetic signatures that predict survival that may ultimately be used to guide therapeutic decision-making. Copyright (C) 2004 by the Society for Gynecologic Investigation.
引用
收藏
页码:51 / 59
页数:9
相关论文
共 23 条
[1]  
Abdollahi A, 1997, CANCER RES, V57, P2029
[2]   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].
Alizadeh, AA ;
Eisen, MB ;
Davis, RE ;
Ma, C ;
Lossos, IS ;
Rosenwald, A ;
Boldrick, JG ;
Sabet, H ;
Tran, T ;
Yu, X ;
Powell, JI ;
Yang, LM ;
Marti, GE ;
Moore, T ;
Hudson, J ;
Lu, LS ;
Lewis, DB ;
Tibshirani, R ;
Sherlock, G ;
Chan, WC ;
Greiner, TC ;
Weisenburger, DD ;
Armitage, JO ;
Warnke, R ;
Levy, R ;
Wilson, W ;
Grever, MR ;
Byrd, JC ;
Botstein, D ;
Brown, PO ;
Staudt, LM .
NATURE, 2000, 403 (6769) :503-511
[3]  
BERCHUCK A, 1994, AM J OBSTET GYNECOL, V170, P246
[4]   REGULATION OF GROWTH OF NORMAL OVARIAN EPITHELIAL-CELLS AND OVARIAN-CANCER CELL-LINES BY TRANSFORMING GROWTH-FACTOR-BETA [J].
BERCHUCK, A ;
RODRIGUEZ, G ;
OLT, G ;
WHITAKER, R ;
BOENTE, MP ;
ARRICK, BA ;
CLARKEPEARSON, DL ;
BAST, RC .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 166 (02) :676-684
[5]  
Boyd JA, 2000, PRINCIPLES PRACTICE, P103
[6]  
Gebauer G, 1999, ANTICANCER RES, V19, P2509
[7]   Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring [J].
Golub, TR ;
Slonim, DK ;
Tamayo, P ;
Huard, C ;
Gaasenbeek, M ;
Mesirov, JP ;
Coller, H ;
Loh, ML ;
Downing, JR ;
Caligiuri, MA ;
Bloomfield, CD ;
Lander, ES .
SCIENCE, 1999, 286 (5439) :531-537
[8]   Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations [J].
Havrilesky, LJ ;
Alvarez, AA ;
Whitaker, RS ;
Marks, JR ;
Berchuck, A .
GYNECOLOGIC ONCOLOGY, 2001, 83 (03) :491-500
[9]   Gene expression profiles, of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers [J].
Jazaeri, AA ;
Yee, CJ ;
Sotiriou, C ;
Brantley, KR ;
Boyd, J ;
Liu, ET .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (13) :990-1000
[10]   SPECTRUM OF MUTATION AND FREQUENCY OF ALLELIC DELETION OF THE P53 GENE IN OVARIAN-CANCER [J].
KOHLER, MF ;
MARKS, JR ;
WISEMAN, RW ;
JACOBS, IJ ;
DAVIDOFF, AM ;
CLARKEPEARSON, DL ;
SOPER, JT ;
BAST, RC ;
BERCHUCK, A .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (18) :1513-1519